Mitsubishi UFJ Asset Management Co. Ltd. Makes New $67.58 Million Investment in West Pharmaceutical Services, Inc. $WST

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 188,231 shares of the medical instruments supplier’s stock, valued at approximately $67,575,000.

Other institutional investors have also modified their holdings of the company. Wealth Alliance LLC lifted its stake in West Pharmaceutical Services by 3.8% during the 1st quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock worth $237,000 after acquiring an additional 35 shares in the last quarter. IFM Investors Pty Ltd grew its position in West Pharmaceutical Services by 0.3% in the 1st quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 43 shares in the last quarter. Compound Planning Inc. increased its stake in West Pharmaceutical Services by 3.6% during the first quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock worth $307,000 after purchasing an additional 43 shares during the period. Aptus Capital Advisors LLC increased its stake in West Pharmaceutical Services by 5.5% during the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after purchasing an additional 47 shares during the period. Finally, Cornerstone Planning Group LLC lifted its position in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 50 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Citigroup raised their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Stephens reissued an “overweight” rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Finally, Evercore restated an “outperform” rating and issued a $425.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and an average target price of $368.08.

West Pharmaceutical Services Price Performance

WST stock opened at $352.32 on Thursday. The business’s 50-day moving average is $347.64 and its two-hundred day moving average is $298.51. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market capitalization of $24.80 billion, a P/E ratio of 45.11, a P/E/G ratio of 2.42 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the company posted $1.84 earnings per share. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.